Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5.9% in the afternoon session after the company ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

GeneCentric, a company making precision medicine more precise by bringing gene expression biology to liquid biopsy, today announced that it will present three posters at the American Association for ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full year’s revenue to be around $870 million, ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...

SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year ...

(RTTNews) - Myriad Genetics, Inc. (MYGN) Monday announced the appointment of Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a ...

Piper Sandler has upgraded Myriad Genetics (NASDAQ:MYGN), a molecular diagnostic testing and precision medicine company. Analyst David Westenberg says Myriad Genetics’ management team set an overly ...

ACLU and PUBPAT Argue Against Patents on Breast Cancer Genes in Appeals Court ACLU and PUBPAT Argue Against Patents on Breast Cancer Genes in Appeals Court ...